Starting on the lowest dose of tirzepatide: what to expect

Why tirzepatide treatment begins at 2.5mg

A lot of people arrive at this question expecting 2.5mg to be a cautious, token gesture before the real treatment begins. It is more purposeful than that. Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1) which slows gastric emptying and reduces appetite. That combination is effective precisely because it is potent, and potency is what makes the introductory period important.

Starting low gives your digestive system time to adapt. Nausea, loose stools and a reduced appetite for food can all arrive at once if the dose jumps too quickly. The 2.5mg starting pen is designed to minimise that early discomfort so that people can stay on treatment long enough for it to work. The full tirzepatide dose schedule (2.5mg through to 15mg) is built on this logic: each step only happens when your system is ready.

One practical note: when your first Mounjaro pen arrives (tracked by DPD, in a plain unbranded box), it will be a 2.5mg KwikPen containing four weekly doses. If you want to understand what the lowest dose of Mounjaro involves, that detail is covered separately, including what to expect from the pen itself and how this starting point fits into the wider titration plan. That information lives in the clinical review that precedes it.

What the lowest dose is not designed to do

It is reasonable to wonder whether 2.5mg will produce any weight change. For some people it does, appetite shifts a little, portions feel smaller, the impulse to snack quietens. For many, the effect at this dose is modest. That is not a failure of the medicine or the person taking it.

The clinical trial evidence that informs NICE's recommendation of tirzepatide (published in the SURMOUNT-1 study in the New England Journal of Medicine) studied outcomes at the higher maintenance doses. Average weight reductions of around 20% over 72 weeks were recorded at 15mg. Those figures are the ceiling, not the floor, and they were reached after a titration period most participants spent working up through lower doses. If you are weighing up whether tirzepatide is right for you, the weight-loss treatment overview sets out the full picture of what the medicine can and cannot do.

The lowest dose is also not a dose you manage independently. Changes in how it sits with you (persistent nausea, unexpected side effects, or conversely a sense that it is settling well) are information for your prescriber, not prompts to adjust the regimen yourself.

Deciding whether to move up from 2.5mg

This is the decision that most people on the lowest dose are really asking about. The answer depends on tolerability, how long you have been at the current dose, and your prescriber's assessment of your response. Clinically, the intention is to titrate upward in roughly 4-week steps, moving to 5mg when 2.5mg is comfortable. You can read more about what the 5mg dose involves if you are approaching that step.

Some people find they tolerate each step easily and move through the schedule without much disruption. Others have a harder time with one particular increase and stay at that level longer. Both are normal. The question of staying on the lowest dose for an extended period is a legitimate clinical conversation, not a problem to be solved. If the 2.5mg dose is causing significant side effects, that is worth raising with your prescriber before assuming the next step up is the answer. The NHS medicines guidance on tirzepatide at nhs.uk/medicines/tirzepatide lists what side effects to monitor and when to seek help, a useful reference alongside your Patient Information Leaflet.

If you have not yet started treatment and want to understand whether tirzepatide is suitable for you, our clinical team reviews consultations the same day, a prescriber, not automated software, reads every response. The clinical team profile explains who is doing that reviewing.

Low-dose tirzepatide and longer-term planning

There is a separate but related question: what happens if the higher doses are never well tolerated? Some people reach a point where, say, 7.5mg causes persistent nausea but 5mg is comfortable. A prescriber can legitimately decide that staying at a lower maintenance dose is the right call. This is not the same as staying at 2.5mg indefinitely, but the principle is similar, the goal is the highest dose that is well tolerated, not the highest dose on the list.

NICE's appraisal of tirzepatide (TA1026, published December 2024) frames continued treatment around meaningful weight-loss response after six months at the highest tolerated dose. The word "tolerated" in that guidance is doing real work. Low-dose tirzepatide options are a clinical reality, and the guidance on low-dose tirzepatide explores that territory in more detail.

When the time comes to consider starting, our prescribers are available for a free consultation. Speak to our prescribers through the consultation page, there is no obligation, and the clinical review is included as part of the service.